Christopher A Thompson

US Patent:

7652049, Jan 26, 2010

Filed:

Jul 1, 2005

Appl. No.:

11/173295

Inventors:

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 263/20
A61K 31/4015

US Classification:

514376, 514340, 514361, 514386, 5462714, 548125, 548224, 5483661

Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:.

US Patent:

7737295, Jun 15, 2010

Filed:

Apr 8, 2005

Appl. No.:

11/578694

Inventors:

Amjad Ali - Freehold NJ, US
Joann Bohn - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07C 261/00
C07C 211/00
A01N 47/10

US Classification:

560115, 560132, 564336, 564337, 514476

Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

US Patent:

7781426, Aug 24, 2010

Filed:

Dec 29, 2006

Appl. No.:

12/087184

Inventors:

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/422
A61K 31/5377
A61K 31/541
A61K 31/496
A61K 31/443
A61K 31/4525
A61K 31/55
C07D 403/02
C07D 413/02
C07D 417/02
C07D 401/02

US Classification:

5142171, 514376, 5142368, 5142278, 51425402, 514340, 514326, 548230, 544137, 544 60, 544369, 5462714, 546209, 540603

Abstract:

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or Ris a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or Ris also a cyclic group.

US Patent:

7910592, Mar 22, 2011

Filed:

Dec 29, 2006

Appl. No.:

12/087185

Inventors:

Amjad Ali - Freehold NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Yi-Heng Chen - Whippany NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Christopher F. Thompson - Clark NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/497
A61K 31/427
A61K 31/422
A61K 31/506
C07D 239/02
C07D 241/02
C07D 401/02
C07D 277/02
C07D 263/02

US Classification:

51425505, 514256, 514365, 514376, 544242, 544336, 5462714, 548202, 548230

Abstract:

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

US Patent:

8193365, Jun 5, 2012

Filed:

Jun 14, 2010

Appl. No.:

12/815146

Inventors:

Amjad Ali - Freehold NJ, US
Joann Bohn - North Plainfield NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle Taylor - Red Bank NJ, US
Christopher Thompson - Clark NJ, US
Nazia Quraishi - Vienna VA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 261/02
C07D 209/04
C07D 307/93
A01N 57/26
A01N 57/00

US Classification:

546348, 548490, 548240, 549462

Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, Aand A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

US Patent:

8334290, Dec 18, 2012

Filed:

Oct 30, 2006

Appl. No.:

12/083324

Inventors:

Amjad Ali - Freehold NJ, US
Julianne A. Hunt - Scotch Plains NJ, US
Florida Kallashi - Laurence Harbor NJ, US
Jennifer Kowalchick - Clark NJ, US
Dooseop Kim - Westfield NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Ramzi F. Sweis - Franklin Park NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Liya Chen - East Brunswick NJ, US
Nazia Quraishi - Vienna VA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/496
A61K 31/497
A61K 31/443
A61K 31/421
C07D 239/42
C07D 413/14
C07D 211/32
C07D 213/26
C07D 263/57

US Classification:

5142531, 51425402, 514318, 514321, 514375, 544332, 544368, 546194, 546198, 548224

Abstract:

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

US Patent:

8604038, Dec 10, 2013

Filed:

Aug 24, 2010

Appl. No.:

13/392282

Inventors:

Scott D. Edmondson - Clark NJ, US
Lehua Chang - Ramsey NJ, US
Nam Fung Kar - Brooklyn NY, US
Christopher R. Moyes - Westfield NJ, US
Cheng Zhu - Edison NJ, US
Neville J. Anthony - Northborough MA, US
Philip Jones - Houston TX, US
Graham F. Smith - Sudbury MA, US
Mark E. Scott - Andover MA, US
Christopher F. Thompson - Arlington MA, US
Joon Jung - Newton MA, US
Carolyn Cammarano - Worcester MA, US
Dawn Marie Hoffman - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/50
A61K 31/525

US Classification:

51425205, 514383, 514343, 514256, 51425505, 514370, 514378, 514303, 514428, 5482676, 548199, 548247, 548570, 5462764, 546118, 544335, 544336, 544238

Abstract:

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

US Patent:

20080119476, May 22, 2008

Filed:

Jul 1, 2005

Appl. No.:

11/631821

Inventors:

Amjad Ali - Freehold NJ, US
Joann M. Napolitano - Woodbridge NJ, US
Qiaolin Deng - Edison NJ, US
Zhijian Lu - Clinton NJ, US
Peter J. Sinclair - Scotch Plains NJ, US
Gayle E. Taylor - Jersey City NJ, US
Christopher F. Thompson - Clark NJ, US
Nazia Quraishi - Arlington MA, US
Cameron J. Smith - Lawrenceville NJ, US
Julianne A. Hunt - Scotch Palins NJ, US
Adrian A. Dowst - Hoboken NJ, US
Yi-Heng Chen - Whippany NJ, US
Hong Li - Edison NJ, US

International Classification:

A61K 31/422
A61K 31/40
A61K 31/4166
A61K 31/427
A61K 31/4439
A61K 31/501
A61P 9/10
C07D 233/32
C07D 263/20
C07D 417/10
C07D 417/04
C07D 413/10
C07D 413/04
C07D 401/04
C07D 285/10
C07D 233/44
C07D 207/24
A61K 31/506
A61K 31/497
A61K 31/433
A61K 31/4168
A61K 31/421

US Classification:

51425205, 51425505, 514256, 514340, 514341, 514362, 514372, 514376, 514392, 514424, 514426, 544238, 544333, 544405, 5462714, 5462741, 548134, 548200, 548229, 5483235, 5483315, 548551

Abstract:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH—.